


CLINICAL RESEARCH PROTOCOLS FOR SUPPORTIVE CARE



CLB-9473, NCI-P97-0097
Phase I/II Study of Omega-3 Fatty Acids in Advanced Cancer Patients With Cachexia

Chairperson: C. Patrick Burns. Telephone: 319-356-2038. Lead organization: Cancer and Leukemia Group B. Age range: 18 and over.

E-1Z95 Phase II Study of Flecainide for the Treatment of Chronic Neuropathic Pain

Chairperson: Charles F. Von Gunten. Lead organization: Eastern Cooperative Oncology Group. Age range: over 18.

NU-98CC6, NCI-G00-1705
Phase II Study of Megestrol and Progressive Resistance Training in Patients With Cancer Related Weight Loss

Chairman: Jamie Hayden Von Roenn. Telephone: 312-695-6180. Lead organization: Robert H. Lurie Comprehensive Cancer Center. Age range: over 18.

NU-97X1, NCI-G00-1685
Phase II Study of Octreotide as Palliative Therapy for Inoperable Bowel Obstruction Secondary to Cancer

Chairperson: J. Cameron Muir. Telephone: 312-908-5250. Lead organization: Robert H. Lurie Comprehensive Cancer Center. Age range: over 18.

NU-98CC7, NCI-G00-1706
Phase II Study of Progressive Resistance Training (PRT) Plus Epoetin Alfa in Cancer Patients With Anemia Related Fatigue

Chairperson: Jamie Hayden Von Roenn. Telephone: 312-695-6180. Lead organization: Robert

H. Lurie Comprehensive Cancer Center, Northwestern University. Age range: over 18.

NCCTG-979253, NCI-P98-0133 Phase III Randomized Study of Epoetin Alfa in Anemic Patients With Advanced Cancer Undergoing Chemotherapy

Chairperson: Thomas E. Witzig. Telephone: 507-284-2176. Lead organization: North Central Cancer Treatment Group. Age range: 18 and over.

IBCSG-17-98, EU-98077 Phase III Randomized Study of Hormone Replacement Therapy in Menopausal or Perimenopausal Women With Prior Stage 0-II Breast Cancer

Chairperson: C. Rageth. Telephone: 0041-1-733-21-76. Lead organization: International Breast Cancer Study Group. Age range: not specified.

NCCTG-989201, NCI-P00-0168 Phase III Randomized Study of Ondansetron in Patients With Advanced Cancer and Chronic Nausea and Emesis Not Due to Antineoplastic Therapy

Chairperson: Steven Alberts. Telephone: 507-284-4918. Lead organization: North Central Cancer Treatment Group. Age range: not specified.

CCCWFU-97300, NCI-P00-0174, CCCWFU-0009 Phase III Randomized Study of the Effect of Megestrol on Weight and Quality of Life in Patients With Head and Neck Cancer

Chairperson: Kathryn McConnell Greven. Telephone: 336-716-4981. Lead organization: Com-

This list of clinical research protocols relating to supportive care is compiled for your convenience.

For more information on these protocols, please call PDQ, a service of the National Cancer Institute, at 1-800-4-CANCER.

A searchable PDQ Web site is also accessible at <http://cancer.net/nci.nih.gov/trialsrch.shtml>

Clinical Research Protocols

prehensive Cancer Center of Wake Forest University Baptist Medical Center. Age range: over 18.

CAN-NCIC-SC17 Phase III Randomized Study of Two Different Sustained Release Formulations of Morphine Followed by Dextromethorphan or Placebo Plus Morphine for Patients With Chronic Cancer Pain

Chairperson: Eduardo Bruera. Telephone: 713-792-6085. Lead organization: NCIC-Clinical Trials Group. Age range: 16 and over.

E-3Z93, NCI-P95-0068 Randomized Pilot Study to Evaluate Educational Intervention and Behavioral Skills Training for Pain Control in Patients With Recurrent or Metastatic Breast or Prostate Cancer

Chairperson: Charles Cleeland. Telephone: 713-745-3470. Lead organization: Eastern Cooperative Oncology Group. Age range: 18 and over.

SJHCH-TM1, NCI-V00-1618 Randomized Study of Stress Reduction in Older Women With Stage II, III, or IV Breast Cancer

Chairperson: Rhoda Pomerantz. Telephone: 773-665-3606. Lead organization: St. Joseph Health Centers & Hospital. Age range: 55 and over.

URCC-3996, NCI-P00-0160 Randomized Study of the Efficacy of Patient Information in Alleviating Nausea and Emesis in Cancer Patients Receiving Chemotherapy

Chairperson: Gary R. Morrow. Telephone: 716-275-5513. Lead organization: University of Rochester Cancer Center. Age range: 18 and over.